FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Esperion Therapeutics, Inc....
04 July 2018 - 4:40AM
Business Wire
The Schall Law Firm, a national shareholder rights litigation
firm, announces the filing of a class action lawsuit against
Esperion Therapeutics, Inc. (“Esperion” or “the Company”) (NASDAQ:
ESPR) for violations of §§10(b) and 20(a) of the Securities
Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the
U.S. Securities and Exchange Commission.
Investors who purchased the Company's shares between February
22, 2017, and May 1, 2018, inclusive (the “Class Period”), are
encouraged to contact the firm before July 6, 2018.
If you are a shareholder who suffered a loss, click here to
participate.
We also encourage you to contact Brian Schall, or Sherin
Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite
404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights
free of charge. You can also reach us through the firm's website
at www.schallfirm.com, or by email
at brian@schallfirm.com.
The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the Complaint, Esperion Therapeutics made
materially false and misleading statements during the class period.
Esperion failed to disclose that Bempedoic acid, the company’s
cholesterol-lowering medication, had serious safety risks up to and
including death. As a result of the failure to disclose this
information, Esperion Therapeutics’ financial statements, claims
about the company’s business operations, and financial prospects
were materially false and misleading throughout the class period.
According to the lawsuit, when accurate information about Esperion
Therapeutics became apparent in the market, investors suffered
damages.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder
rights litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and rules of
ethics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180703005534/en/
The Schall Law FirmBrian Schall, Esq.Sherin Mahdavian,
Esq.www.schallfirm.com310-301-3335info@schallfirm.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Apr 2024 to May 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From May 2023 to May 2024